Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BAY 2927088 versus standard therapy in advanced HER2-mutant non-squamous NSCLC
MOH_2024-08-08_013489Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevabertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bayer. Started Jul 2024; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-08-08_013489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-08_013489.